References
- ReginsterJYBurletNOsteoporosis: a still increasing prevalenceBone2006382 Suppl 1S4S916455317
- RotellaDPOsteoporosis: challenges and new opportunities for therapyCurr Opin Drug Discov Devel200254477486
- BonuraFPrevention, screening, and management of osteoporosis: an overview of the current strategiesPostgrad Med2009121451719641263
- WHOPrevention and management of osteoporosisWorld Health Organ Tech Rep Ser2003921116415293701
- KanisJAOdenAJohnellOThe use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and womenOsteoporos Int200781033104617323110
- KanisJFRAXTM WHO fracture risk assessment toolhttp://wwwshe-facuk/FRAX/indexhtm Accessed September15, 2009.
- BonnickSLShulmanLMonitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?Am J Med20061194 Suppl 1S25S3116563938
- CurtisJRWestfallAOChengHDelzellESaagKGRisk of hip fracture after bisphosphonate discontinuation: implications for a drug holidayOsteoporos Int200819111613162018483689
- EastellRTreatment of postmenopausal osteoporosisN Engl J Med1998338117367469494151
- BarrettJWorthEBaussFEpsteinSIbandronate: a clinical pharmacological and pharmacokinetic updateJ Clin Pharmacol200444995196515317823
- WaknineYZoledronic acid injection approved to prevent postmenopausal osteoporosis2009Available from: http://www.medscape.com/viewarticle/703898 Accessed December 31, 2009.
- FDA Approves Zometa (Zoledronic Acid) for Hypercalcemia of MalignancyAvailable at: http://www.docguide.com/news/content.nsf/news/00EF3B1D01A2414585256AAF004B4646 Accessed May 26, 2010.
- LiECDavisLEZoledronic acid: a new parenteral bisphosphonateClin Ther200325112669270814693298
- KeatingGMScottLJZoledronic acid: a review of its use in the treatment of Paget’s disease of boneDrugs200767579380417385948
- DeeksEDPerryCMZoledronic acid: a review of its use in the treatment of osteoporosisDrugs Aging2008251196398618947264
- WellingtonKGoaKLZoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancyDrugs200363441743712558465
- RingeJZoledronic acid in the treatment of Paget’s disease and other benign bone disordersExpert Rev Endocrinol Metab2006111524
- RussellRGBisphosphonates: from bench to bedsideAnn N Y Acad Sci2006106836740116831938
- NancollasGHTangRPhippsRJNovel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatiteBone200638561762716046206
- CoxonFPHelfrichMHVan’t HofRProtein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298J Bone Miner Res20001581467147610934645
- FromigueOBodyJJBisphosphonates influence the proliferation and the maturation of normal human osteoblastsJ Endocrinol Invest200225653954612109626
- von KnochFJaquieryCKowalskyMEffects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cellsBiomaterials200526346941694916009417
- KavanaghKLGuoKDunfordJEThe molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugsProc Natl Acad Sci U S A2006103207829783416684881
- DunfordJEThompsonKCoxonFPStructure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonatesJ Pharmacol Exp Ther2001296223524211160603
- ReidIRBrownJPBurckhardtPIntravenous zoledronic acid in postmenopausal women with low bone mineral densityN Engl J Med2002346965366111870242
- DevogelaerJPBrownJPBurckhardtPZoledronic acid efficacy and safety over five years in postmenopausal osteoporosisOsteoporos Int20071891211121817516022
- ReckerRStakkestadJAChesnutCHInsufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosisBone200434589089915121021
- BlackDMDelmasPDEastellROnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
- HarrisSTWattsNBGenantHKEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study GroupJama1999282141344135210527181
- ReginsterJMinneHWSorensenOHRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporos Int2000111839110663363
- ChesnutICSkagAChristiansenCEffects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res20041981241124915231010
- SirisEAdachiJDLuYEffects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene EvaluationOsteoporos Int2002131190791312415439
- BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet19963489041153515418950879
- MillerPDMcClungMRMacoveiLMonthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE studyJ Bone Miner Res20052081315132216007327
- ReginsterJYWilsonKMDumontEBonvoisinBBarrettJMonthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot studyJ Clin Endocrinol Metab20059095018502415972582
- ReckerRRDelmasPDHalseJEffects of intravenous zoledronic acid once yearly on bone remodeling and bone structureJ Bone Miner Res200823161617892374
- McClungMReckerRMillerPIntravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronateBone200741112212817468062
- SaagKLindsayRKriegmanABeamerEZhouWA single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral densityBone20074051238124317347063
- McClungMMillerPRecknorCMesenbrinkPBucci-RechtwegCBenhamouCLZoledronic acid for the prevention of bone loss in postmenopausal women with low bone massObstet Gynecol2009114519
- GreyABollandMJWattieDHorneAGambleGReidIRThe anti-resorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal womenJ Clin Endocrinol Metab200994253854419050050
- BoonenSAutierPBaretteMVanderschuerenDLipsPHaentjensPFunctional outcome and quality of life following hip fracture in elderly women: a prospective controlled studyOsteoporos Int2004152879414605799
- Colon-EmericCKuchibhatlaMPieperCThe contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studiesOsteoporos Int2003141187988314530910
- LylesKWColon-EmericCSMagazinerJSZoledronic acid and clinical fractures and mortality after hip fractureN Engl J Med20073571799180917878149
- EriksenEFLylesKWColon-EmericCSAntifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fractureJ Bone Miner Res20092471308131319257818
- HaneyEMBliziotesMMMale osteoporosis: new insights in an understudied diseaseCurr Opin Rheumatol200820442342818525355
- BoonenSMagazinerJLylesKWEffect of once-yearly i.v. zoledronic acid in men after hip fracture: results from the horizon-recurrent fracture trial [abstract no. P251]Osteoporos Int200920Suppl 1S23S176
- Colon-EmericCSMesenbrinkPLylesKWPotential mediators of the mortality reduction with zoledronic acid after hip fractureJ Bone Miner Res2009251919719580467
- OrwollEMillerPAdachiJOnce-yearly i.v. zoledronic acid 5 mg versus weekly oral alendronate 70 mg in men with osteoporosisENDO 2009Abstracts2View OnlineAbstract OR13-3. Chevy Chase, MDThe Endocrine Society2009http://www.endo-society.org/endo09/ Accessed February 1, 2010.
- LetochaADCintasHLTroendleJFControlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvementJ Bone Miner Res200520697798615883638
- DimeglioLAFordLMcClintockCPeacockMA comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfectaJ Pediatr Endocrinol Metab2005181435315679068
- SeikalyMGKopanatiSSalhabNImpact of alendronate on quality of life in children with osteogenesis imperfectaJ Pediatr Orthop200525678679116294137
- BrownJJZacharinMRSafety and efficacy of intravenous zoledronic acid in paediatric osteoporosisJ Pediatr Endocrinol Metab2009221556319344075
- BoonenSBlackDMColón-EmericCSEfficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly osteoporotic postmenopausal women aged 75 years and olderJ Am Geriatr Soc201058229229920070415
- Van StaaTPLeufkensHGAbenhaimLZhangBCooperCOral corticosteroids and fracture risk: relationship to daily and cumulative dosesRheumatology (Oxford)200039121383138911136882
- Van StaaTPLeufkensHGAbenhaimLZhangBCooperCUse of oral corticosteroids and risk of fracturesJ Bone Miner Res2000156993100010841167
- Van StaaTPLeufkensHGCooperCThe epidemiology of corticosteroid-induced osteoporosis: a meta-analysisOsteoporos Int2002131077778712378366
- DevogelaerJPGoemaereSBoonenSEvidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone ClubOsteoporos Int200617181916217586
- American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced OsteoporosisRecommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced OsteoporosisArthritis Rheum20014471496150311465699
- ReidDMDevogelaerJPSaagKZoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trialLancet200937396711253126319362675
- OtrockZKAzarSTShamseddeenWAIntravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trialAnn Hematol200685960560916830143
- OtrockZKMahfouzRACharafeddineKMRayesRFZahedLFTaherATVitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosisAnn Hematol2008871194794818443790
- VoskaridouEAnagnostopoulosAKonstantopoulosKZoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trialHaematologica20069191193120216956818
- VoskaridouEChristoulasDKonstantinidouMTsiftsakisEAlexakosPTerposEContinuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trialHaematologica200893101588159018698086
- RingeJDFarahmandPDorstAIntravenous zoledronic acid: a rapid and very effective treatment in localized transient osteoporosis of the hipOsteologie20071628
- ReidIRMillerPLylesKComparison of a single infusion of zoledronic acid with risedronate for Paget’s diseaseN Engl J Med2005353989890816135834
- HoskingDLylesKBrownJPLong-term control of bone turnover in Paget’s disease with zoledronic acid and risedronateJ Bone Miner Res200722114214817032148
- MercadanteSMalignant bone pain: pathophysiology and treatmentPain1997691–21189060007
- SaadFGleasonDMMurrayRA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst200294191458146812359855
- RosenLSGordonDKaminskiMZoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trialCancer J20017537738711693896
- RosenLSGordonDKaminskiMLong-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trialCancer20039881735174414534891
- RosenLSGordonDTchekmedyianSZoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJ Clin Oncol200321163150315712915606
- BhoopalamNCampbellSCMoritzTIntravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapyJ Urol200918252257226419758618
- Zoledronic acid in prevention of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal womenAHFS Drug Information® Off-label Use Determinations2008Available from: http://www.ahfsdruginformation.com/off_label/tables/Zoledronic_Acid.pdf Accessed May 26, 2010.
- DemontieroODuqueGOnce-yearly zoledronic acid in hip fracture preventionClin Interv Aging20094115316419503777
- GrbicJTLandesbergRLinSQIncidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trialJ Am Dent Assoc20081391324018167382
- ReginsterJYRabendaVPatient preference in the management of postmenopausal osteoporosis with bisphosphonatesClin Interv Aging20061441542318046918
- EastellRGarneroPVrijensBInfluence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT studyCalcif Tissue Int200372408
- SebaldtRJShaneLPhamBLonger-term effectiveness outcomes of non-compliance and non-persistence with daily-regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist careOsteoporos Int200415Suppl 1S107
- CaroJJIshakKJHuybrechtsKFRaggioGNaujoksCThe impact of compliance with osteoporosis therapy on fracture rates in actual practiceOsteoporos Int200415121003100815167989
- HarrisSTSirisEAbbottTBarrCEHarrisSRosenCReduced osteoporotic fracture risk in patients adherence to bisphosphonate therapyProgram and Abstracts of The Endocrine Society’s 87th Annual Meeting2005 June 4–720053382
- SirisEHarrisSSilvermanSAbbottTBarrCRosenCAdherence to bisphosphonates (BPs) is associated with reduced fracture risk in women with postmenopausal osteoporosis (PMO)Menopause200512807
- CummingsSRBlackDMThompsonDEEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJama199828024207720829875874
- BoneHGAdamiSRizzoliRWeekly administration of alendronate: rationale and plan for clinical assessmentClin Ther2000221152810688387
- SchnitzerTBoneHGCrepaldiGTherapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupAging (Milano)20001211210746426
- BrownJPKendlerDLMcClungMRThe efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosisCalcif Tissue Int200271210311112085156
- CooperCEmkeyRDMcDonaldRHEfficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosisJ Clin Endocrinol Metab200388104609461514557430
- ReginsterJYAdamiSLakatosPEfficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE studyAnn Rheum Dis200665565466116339289
- DelmasPDBenhamouCLManZMonthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety resultsOsteoporos Int20081971039104518087660
- DelmasPDMcClungMRZanchettaJREfficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisBone2008421364217920005
- DelmasPDAdamiSStrugalaCIntravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration studyArthritis Rheum20065461838184616729277
- SunyeczJOptimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerationsClin Interv Aging20083461162719281054
- CramerJAGoldDTSilvermanSLLewieckiEMA systematic review of persistence and compliance with bisphosphonates for osteoporosisOsteoporos Int20071881023103117308956
- SorensenOHCrawfordGMMulderHLong-term efficacy of risedronate: a 5-year placebo-controlled clinical experienceBone200332212012612633783
- DoggrellSAClinical efficacy and safety of zoledronic acid in prostate and breast cancerExpert Rev Anticancer Ther2009991211121819761424